Cornelia G. Meeuwsen-Van Helden

Rotterdam, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Exaggerated IFN-I Response in Long COVID PBMCs Following Exposure to Viral Mimics.

Exaggerated IFN-I Response in Long COVID PBMCs Following Exposure to Viral Mimics.

Journal: Journal of clinical immunology

Published: April 28, 2025

Amlexanox inhibits production of type I interferon and suppresses B cell differentiation in vitro: a possible therapeutic option for systemic lupus erythematosus and other systemic inflammatory diseases.

Amlexanox inhibits production of type I interferon and suppresses B cell differentiation in vitro: a possible therapeutic option for systemic lupus erythematosus and other systemic inflammatory diseases.

Journal: RMD open

Published: December 19, 2024

Leflunomide/hydroxychloroquine combination therapy targets type I IFN-associated proteins in patients with Sjögren's syndrome that show potential to predict and monitor clinical response.

Leflunomide/hydroxychloroquine combination therapy targets type I IFN-associated proteins in patients with Sjögren's syndrome that show potential to predict and monitor clinical response.

Journal: RMD open

Published: January 02, 2023

Extranodal marginal zone lymphoma clonotypes are detectable prior to eMZL diagnosis in tissue biopsies and peripheral blood of Sjögren's syndrome patients through immunogenetics.

Extranodal marginal zone lymphoma clonotypes are detectable prior to eMZL diagnosis in tissue biopsies and peripheral blood of Sjögren's syndrome patients through immunogenetics.

Journal: Frontiers in oncology

Published: December 23, 2022

Serum IFNα2 levels are associated with disease activity and outperform IFN-I gene signature in a longitudinal childhood-onset SLE cohort.

Serum IFNα2 levels are associated with disease activity and outperform IFN-I gene signature in a longitudinal childhood-onset SLE cohort.

Journal: Rheumatology (Oxford, England)

Published: September 06, 2022

Targeted multiomics in childhood-onset SLE reveal distinct biological phenotypes associated with disease activity: results from an explorative study.

Targeted multiomics in childhood-onset SLE reveal distinct biological phenotypes associated with disease activity: results from an explorative study.

Journal: Lupus science & medicine

Published: August 08, 2022

Trained Immunity in Primary Sjögren's Syndrome: Linking Type I Interferons to a Pro-Atherogenic Phenotype.

Trained Immunity in Primary Sjögren's Syndrome: Linking Type I Interferons to a Pro-Atherogenic Phenotype.

Journal: Frontiers in immunology

Published: December 21, 2021

Blood myxovirus resistance protein-1 measurement in the diagnostic work-up of suspected COVID-19 infection in the emergency department.

Blood myxovirus resistance protein-1 measurement in the diagnostic work-up of suspected COVID-19 infection in the emergency department.

Journal: Immunity, inflammation and disease

Published: December 21, 2021

Gene signature fingerprints stratify SLE patients in groups with similar biological disease profiles: a multicentre longitudinal study.

Gene signature fingerprints stratify SLE patients in groups with similar biological disease profiles: a multicentre longitudinal study.

Journal: Rheumatology (Oxford, England)

Published: November 05, 2021

Hyperresponsive cytosolic DNA-sensing pathway in monocytes from primary Sjögren's syndrome.

Hyperresponsive cytosolic DNA-sensing pathway in monocytes from primary Sjögren's syndrome.

Journal: Rheumatology (Oxford, England)

Published: October 13, 2021

Serum interferon-α2 measured by single-molecule array associates with systemic disease manifestations in Sjögren's syndrome.

Serum interferon-α2 measured by single-molecule array associates with systemic disease manifestations in Sjögren's syndrome.

Journal: Rheumatology (Oxford, England)

Published: April 02, 2021

MxA is a clinically applicable biomarker for type I interferon activation in systemic lupus erythematosus and systemic sclerosis.

MxA is a clinically applicable biomarker for type I interferon activation in systemic lupus erythematosus and systemic sclerosis.

Journal: Rheumatology (Oxford, England)

Published: February 11, 2019

Showing 1-12 of 27

Last Updated: 09/26/2026